TY - JOUR
T1 - Psychedelics and health behaviour change
AU - Teixeira, Pedro J.
AU - Johnson, Matthew W.
AU - Timmermann, Christopher
AU - Watts, Rosalind
AU - Erritzoe, David
AU - Douglass, Hannah
AU - Kettner, Hannes
AU - Carhart-Harris, Robin L.
N1 - Funding Information:
PJT is the research director at The Synthesis Institute B.V.. MWJ is an advisor to AWAKN Life Sciences Inc., Beckley Psytech Ltd., Entheogen Biomedical Corp., Field Trip Psychedelics Inc., Mind Medicine Inc., Otsuka Pharmaceutical Development & Commercialization Inc., and Silo Pharma, Inc.; CT is an advisor for Entheon Biomedical Corp; RW is a member of the Clinical Advisory Board of the Usona Institute; and clinical director at The Synthesis Institute B.V.. DE is an advisor for Field Trip Psychedelics Inc. and Mydecine Innovations Group Inc. HD was funded by the Imperial College London President’s PhD Scholarships. RCH is a scientific advisor for Entheon Biomedical Corp., Mydecine Innovations Group Inc., The Synthesis Institute B.V., Usona Institute, Beckley Psychtech Ltd., Maya PBC, Osmind PBC, and TRYP Therapeutics Inc. HK declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Funding Information:
PJT was partially funded by Fundação para a Ciência e Tecnologia, under Grant UIDB/00447/2020 to CIPER. All other authors received no financial support for the research, authorship, and/or publication of this article.
Publisher Copyright:
© The Author(s) 2021.
PY - 2022/1
Y1 - 2022/1
N2 - Healthful behaviours such as maintaining a balanced diet, being physically active and refraining from smoking have major impacts on the risk of developing cancer, diabetes, cardiovascular diseases and other serious conditions. The burden of the so-called ‘lifestyle diseases’—in personal suffering, premature mortality and public health costs—is considerable. Consequently, interventions designed to promote healthy behaviours are increasingly being studied, e.g., using psychobiological models of behavioural regulation and change. In this article, we explore the notion that psychedelic substances such as psilocybin could be used to assist in promoting positive lifestyle change conducive to good overall health. Psilocybin has a low toxicity, is non-addictive and has been shown to predict favourable changes in patients with depression, anxiety and other conditions marked by rigid behavioural patterns, including substance (mis)use. While it is still early days for modern psychedelic science, research is advancing fast and results are promising. Here we describe psychedelics’ proposed mechanisms of action and research findings pertinent to health behaviour change science, hoping to generate discussion and new research hypotheses linking the two areas. Therapeutic models including psychedelic experiences and common behaviour change methods (e.g., Cognitive Behaviour Therapy, Motivational Interviewing) are already being tested for addiction and eating disorders. We believe this research may soon be extended to help promote improved diet, exercise, nature exposure and also mindfulness or stress reduction practices, all of which can contribute to physical and psychological health and well-being.
AB - Healthful behaviours such as maintaining a balanced diet, being physically active and refraining from smoking have major impacts on the risk of developing cancer, diabetes, cardiovascular diseases and other serious conditions. The burden of the so-called ‘lifestyle diseases’—in personal suffering, premature mortality and public health costs—is considerable. Consequently, interventions designed to promote healthy behaviours are increasingly being studied, e.g., using psychobiological models of behavioural regulation and change. In this article, we explore the notion that psychedelic substances such as psilocybin could be used to assist in promoting positive lifestyle change conducive to good overall health. Psilocybin has a low toxicity, is non-addictive and has been shown to predict favourable changes in patients with depression, anxiety and other conditions marked by rigid behavioural patterns, including substance (mis)use. While it is still early days for modern psychedelic science, research is advancing fast and results are promising. Here we describe psychedelics’ proposed mechanisms of action and research findings pertinent to health behaviour change science, hoping to generate discussion and new research hypotheses linking the two areas. Therapeutic models including psychedelic experiences and common behaviour change methods (e.g., Cognitive Behaviour Therapy, Motivational Interviewing) are already being tested for addiction and eating disorders. We believe this research may soon be extended to help promote improved diet, exercise, nature exposure and also mindfulness or stress reduction practices, all of which can contribute to physical and psychological health and well-being.
KW - Psilocybin
KW - interventions
KW - public health
KW - serotonin
KW - therapy
UR - http://www.scopus.com/inward/record.url?scp=85107116105&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85107116105&partnerID=8YFLogxK
U2 - 10.1177/02698811211008554
DO - 10.1177/02698811211008554
M3 - Review article
C2 - 34053342
AN - SCOPUS:85107116105
SN - 0269-8811
VL - 36
SP - 12
EP - 19
JO - Journal of Psychopharmacology
JF - Journal of Psychopharmacology
IS - 1
ER -